NLS Pharmaceutics (NLSP) Competitors $3.29 +0.11 (+3.46%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NLSP vs. XCUR, AFMD, TARA, DBVT, ACAB, IMMX, GANX, CALC, SCYX, and SNYRShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Exicure (XCUR), Affimed (AFMD), Protara Therapeutics (TARA), DBV Technologies (DBVT), Atlantic Coastal Acquisition Corp. II (ACAB), Immix Biopharma (IMMX), Gain Therapeutics (GANX), CalciMedica (CALC), SCYNEXIS (SCYX), and Synergy CHC Corp. (Uplisting) (SNYR). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Exicure Affimed Protara Therapeutics DBV Technologies Atlantic Coastal Acquisition Corp. II Immix Biopharma Gain Therapeutics CalciMedica SCYNEXIS Synergy CHC Corp. (Uplisting) NLS Pharmaceutics (NASDAQ:NLSP) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership. Is NLSP or XCUR more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Exicure N/A -190.90%-36.75% Do insiders and institutionals believe in NLSP or XCUR? 42.8% of Exicure shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 3.9% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in NLSP or XCUR? Exicure received 1 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. However, 57.14% of users gave NLS Pharmaceutics an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% ExicureOutperform Votes947.37% Underperform Votes1052.63% Which has higher valuation & earnings, NLSP or XCUR? NLS Pharmaceutics has higher earnings, but lower revenue than Exicure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$12.17MN/AN/AExicure$28.83M0.84-$16.91M-$2.07-5.41 Which has more volatility & risk, NLSP or XCUR? NLS Pharmaceutics has a beta of -0.51, meaning that its share price is 151% less volatile than the S&P 500. Comparatively, Exicure has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Does the media prefer NLSP or XCUR? In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. Exicure's average media sentiment score of 0.42 beat NLS Pharmaceutics' score of 0.20 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNLS Pharmaceutics and Exicure tied by winning 5 of the 10 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.13M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book0.3010.216.946.30Net Income-$12.17M$153.61M$119.12M$225.93M7 Day Performance-1.50%-2.00%-1.84%-1.32%1 Month Performance-30.88%-7.47%-3.65%0.60%1 Year Performance702.44%31.80%31.64%26.23% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS Pharmaceutics1.2066 of 5 stars$3.29+3.5%N/A+623.1%$12.13MN/A0.006Gap DownXCURExicure1.7834 of 5 stars$11.19+92.3%N/A+1,914.4%$12.64M$28.83M0.0050News CoverageGap UpHigh Trading VolumeAFMDAffimed3.2493 of 5 stars$2.72-9.3%$16.00+488.2%-42.7%$48.30M$8.95M0.0076Analyst ForecastHigh Trading VolumeTARAProtara Therapeutics2.1378 of 5 stars$2.31-0.4%$24.00+939.0%+102.6%$47.86MN/A0.0030Analyst RevisionDBVTDBV Technologies3.2676 of 5 stars$0.51+4.1%$6.00+1,081.1%-70.2%$47.38M$15.73M0.00106Stock SplitGap UpACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.6%$47.14MN/A0.004High Trading VolumeIMMXImmix Biopharma2.28 of 5 stars$1.82+7.1%$7.00+284.6%-58.7%$46.76MN/A0.009Negative NewsHigh Trading VolumeGANXGain Therapeutics2.4867 of 5 stars$1.66-3.5%$7.33+341.8%-39.0%$45.62M$50,000.000.0020News CoverageGap DownCALCCalciMedica3.0723 of 5 stars$3.45+3.0%$19.33+460.4%+10.6%$45.16MN/A0.0030SCYXSCYNEXIS2.1937 of 5 stars$1.18flatN/A-28.5%$44.78M$140.14M0.0060Positive NewsSNYRSynergy CHC Corp. (Uplisting)N/A$5.82-1.4%N/AN/A$44.57MN/A0.0040Gap Up Related Companies and Tools Related Companies Exicure Alternatives Affimed Alternatives Protara Therapeutics Alternatives DBV Technologies Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Immix Biopharma Alternatives Gain Therapeutics Alternatives CalciMedica Alternatives SCYNEXIS Alternatives Synergy CHC Corp. (Uplisting) Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLSP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLSP Stock Alerts